Association of cyclin D1 genotype with breast cancer risk and survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 1, 2005, Pages 91-97

  Xiao, Ou Shu ^a,c   Moore, Derek B ^a   Cai, Qiuyin ^a   Cheng, Jiarong ^b   Wen, Wanqing ^a   Pierce, Larry ^a   Cai, Hui ^a   Gao, Yu Tang ^b   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANGHAI CANCER INSTITUTE   (China)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ALLELE; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL TRANSFORMATION; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DNA EXTRACTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALLELES; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; CYCLIN D1; DATA COLLECTION; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SURVIVAL ANALYSIS;

EID: 12844252435     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Zhou P, Jiang W, Weghorst CM, Weinstein IB. Overexpression of cyclin D1 enhances gene amplification. Cancer Res 1996;56:36-9.
3. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
4. Buckley M, Sweeney K, Hamilton J, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
5. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-61.
6. Gillett C, Fanti V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-7.
7. Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 2001;3:91-4.
8. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 2002;4:14-7.
9. Zhou Q, Hopp T, Fuqua SA, Steeg PS. Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett 2001;162:3-17.
10. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998;52:1-15,
11. Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 2002;86:580-6.
12. Terry MB, Gammon MD, Schoenberg JB, Brinton LA, Arber N, Hibshoosh H. Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 2002;11:1100-3.
13. Turner BC, Gumbs AA, Carter D, Glazer PM, Haffty BG. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. Int J Radiat Oncol Biol Phys 2000;47:1169-76.
14. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-11.
15. Kong S, Wei Q, Amos CI, et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 2001;93:1106-8.
16. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249-52.
17. Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 2003;290:2843-8.
18. Zhang J, Li Y, Wang R, et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 2003;105:281-4.
19. Zheng Y, Shen H, Sturgis EM, et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 2001;22:1195-9.
20. Wang L, Habuchi T, Takahashi T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 2002;23:257-64.
21. Wang L, Habuchi T, Mitsumori K, et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003;103:116-20.
22. Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case-control study of cyclin D1 CCND1 870A → G polymorphism and bladder cancer. Carcinogenesis 2003;24:1645-50.
23. Wong YK, Lin SC, Chang CS, et al. Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 2003;32:265-70.
24. Yu C, Lu W, Tan W, et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2003;12:176.
25. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003;95:198-205.
26. Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 2003;23:4257-9.
27. Dhar KK, Branigan K, Howells RE, et al. Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int J Gynecol Cancer 1999;9:342-7.
28. Matthias C, Branigan K, Jahnke V, et al. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 1998;4:2411-8.
29. Krippl P, Langsenlehner U, Renner W, et al. The 870G > A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 2003;82:165-8.
30. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000;87:295-300.
31. Shu XO, Cai Q, Gao YT, Wen W, Jin F, Zheng W. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1462-7.
32. McKay JA, Douglas JJ, Ross VG, et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 2000;88:77-81.
33. Breslow N, Day NE. Statistical methods in cancer research: analysis of case-control studies. Lyon: IARC Scientific Publications; 1980.
34. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003;278:30339-47.
35. Lewis RC, Bostick RM, Xie D, et al. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res 2003;63:8549-53.
36. Foster JS, Henley DC, Ahamed S, Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001;12:320-7.
37. Key TJ, Verkasalo PK. Endogenous hormones and the aetiology of breast cancer. Breast Cancer Res 1999;1:18-21.
38. Yu H, Shu XO, Shi R, et al. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer 2003;105:92-7.
39. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
40. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.
41. Shu XO, Jin F, Dai Q, et al. Association of body size and fat distribution with risk of breast cancer among Chinese women. Int J Cancer 2001;94:449-55.
42. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003;5:239-47.
43. Vermeulen V, Verdonck L. Sex hormone concentrations in postmenopausal women. Clin Endocrinol (Oxf) 1978;9:59-66.
44. Boyapati SM, Shu XO, Gao YT, et al. Correlation of blood sex steroid hormones with body size, body fat distribution, and other known risk factors for breast cancer in post-menopausal Chinese women. Cancer Causes Control 2004;15:305-11.
45. Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 1990;131:794-803.
46. Kaaks R, Van Noord PA, Den TI, Peeters PH, Riboli E, Grobbee DE. Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch "DOM" cohort. Int J Cancer 1998;76:647-51.
47. Huang Z, Willett WC, Colditz GA, et al. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 1999;150:1316-24.
48. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003;4:157-73.
49. Altucci L, Addeo R, Cicatiello L, et al. 17-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996;12:2315-24.
50. Zafonte BT, Hulit J, Amanatullah DF, et al. Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Front Biosci 2000;5:D938-61.
51. Zhang YJ, Chen SY, Chen CJ, Santella RM. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 2002;33:125-9.
52. Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 2001;27-35.